tamuzimod

Tamuzimod is an orally bioavailable small molecule that acts as a highly selective modulator of sphingosine-1-phosphate receptor subtype 1 (S1PR1). It is being developed for the treatment of moderately to severely active ulcerative colitis. In phase 2 trials, tamuzimod demonstrated high rates of clinical and endoscopic remission at both 13 and 52 weeks and a favorable safety profile compared to other oral options for ulcerative colitis therapy. Mechanistically, tamuzimod limits the egress of lymphocytes from lymph nodes, decreasing their infiltration into inflamed tissues and thereby reducing chronic intestinal inflammation. It is not currently approved and is being developed by Ventyx Biosciences and was originally discovered by Oppilan Pharma[1][2][3][4][7][9].

Brand names

tamuzimod

Other names

tamuzimodtamuzimod [INN]Tamuzimod (USAN/INN)TAMUZIMOD [USAN]tamuzimod acetate